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1. Introduction 
Chronic systemic inflammation and immune dysregulation, as a consequence of primary or 
secondary vasculitis, has been emphasized in pathogenesis of coronary artery disease. 
(Gasparyan & Ugurlucan, 2008; Mukhtyar et al., 2009; Turesson et al., 2008). Severe coronary 
artery disease in absence of obvious serious risk factors, especially in young age, remains a 
challenge to modern cardiology. In these cases, possible relation of ischemic heart disease to 
systemic vasculitis or thrombophilic predisposition should be also examined. (Kaplan 2009; 
Knockaert 2007; Tenedios et al., 2006). 
Henoch-Schonlein Purpura is a rare disease characterized by systemic vasculitis 
(Agraharkar et al., 2000; Satoh et al., 1991). It is rarely related with acute myocardial 
infarction or multivessel disease. (Abdel-Hadi et al., 1981; Eleftheriadis, 2007a; Lutz et al., 
2009; Osman & McCreery, 2000). (Table 1) 
An atypical presentation of severe acute myocardial infarction in a young male with 
Henoch-Schonlein Purpura in remission and no other risk factors for coronary artery disease 
is reported and discussed. After meticulous investigation, including complete blood 
examinations for thrombophilic diathesis, antiphospholipid antibodies and autoimmunity, it 
was concluded that severe acute myocardial infarction in this case was a consequence of 
latent systemic vasculitis in the setting of Henoch-Schonlein Purpura. 
The relation of coronary artery disease with primary or secondary vasculitides is also 
reviewed. Early suspicion and recognition of vasculitis in atypical cases and early initiation 
of appropriate treatment, including corticosteroids and immunosuppressives, may become 
the only optional strategy for prevention of vasculitis-related coronary lesions and life-
threatening infarctions on the ground of undiagnosed systemic vasculitis.  
Key Words: coronary artery disease, acute myocardial infarction, coronary aneurysms, 
systemic vasculitis, Henoch-Schonlein Purpura, Kawasaki disease, polyarteritis nodosa, 
systemic lupus erythematosis, Wegener’s granulomatosis, antiphospholipid syndrome, 
polyangiitis overlap syndrome, Churg-Strauss syndrome, Takayasu arteritis. 
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2. Severe coronary artery disease in the setting of Henoch-Schoenlein 
purpura: Case report 
2.1 Case report 
A 49-year-old male with acute myocardial infarction and Henoch-Schoenlein purpura in 
remission for 10-years, is reported. The patient was admitted with chest pain. Laboratory 
examination showed elevation of cardiac enzymes, while the 12-lead electrocardiogram 
demonstrated ST elevation (up to five mm) in leads II, III, and aVF.  
He had a previous history of acute glomerulonephritis for ten-years, which was finally 
attributed to Henoch-Schonlein Purpura, after detailed clinico-laboratory investigation in 
tertiary center. At that time, total immunological examination did not reveal any other 
autoimmune disease, neither systemic lupus erythematosis nor other known vasculitis. 
Thereafter, he was totally asymptomatic with normal renal function. During ten-year 
follow-up, he had no other admissions, used no medications and had no personal or family 
history of thrombotic events.  
Except for b-blockers use for arterial hypertension, he reported no other medications, 
smoking or alcohol use. All other personal and family history was negative for coronary 
artery disease.  
Clinical examination revealed: blood pressure: 120/80 mmHg, heart rate 50/1min. Urine 
examination showed mild haematuria. Laboratory examination showed: urea 42mg/dl, 
creatinin 1.1mg/dl (normal<1.3), cholesterol: 197mg/dl, (normal<200mg/dl), LDL 
135mg/dl (normal <150), triglycerides 96mg/dl (normal <150mg/dl), HDL 47mg/dl 
(normal >35mg/dl), ESR 54/1h (normal <8/1h), CRP 16.22 mg/dl, (normal <0.8). All other 
hematological, blood chemistry results and thorax photo were normal.  
The patient was successfully treated in intensive care unit for acute myocardial infarction, 
while no thrombolysis was given due to delay arrival. Angiography showed three-vessel 
disease (right coronary artery 100%, middle circumflex artery 75% and left anterior 
descending artery 50%) and angioplasty was performed in two vessels. 
Blood examinations for thrombophilic diathesis were performed. All known risk factors 
associated with increased risk of thrombosis, such as antiphospholipid antibodies, 
coagulation factors, protein C, protein S, factor V Leiden, mutation G20210A of prothrombin 
[PTHR A(20210)], and mutation TT677 of methylenetetrahydrofolate reductase [MTHFR 
C677-->T]), were within normal.  
Thereafter, the patient is under continuous combined anticoagulation with low dose aspirin 
plus clopidogrel. During five-year follow-up post-infarction the patient is totally 
asymptomatic and he is under continuous antianginal agents. No corticosteroids or 
immunosuppressive drugs were administered. 
2.2 Discussion 
Henoch-Schonlein Purpura is a rare disease, characterized by systemic vasculitis of the skin 
and other abdominal organs (Agraharkar et al., 2000; Satoh et al., 1991). It has good 
prognosis, except if it is complicated by severe glomerular disease (Watanabe et al., 2003). 
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Although, it has been extensively studied in children, its natural history in adults is less 
known, with outcome worse in adults than in children. (Pillebout et al., 2002). Correlation 
with acute myocardial infarction or multivessel disease has been rarely reported (Abdel-
Hadi et al., 1981; Eleftheriadis, 2007; Lutz et al., 2009; Osman & McCreery, 2000). (Table 1) 
An interesting finding of the present case, is the discrepancy between absence of serious risk 
factors for coronary artery disease in a young patient and severity of infarction (three-vessel 
disease), which was also reported in two similar cases, with thrombotic thrombocytopenic 
purpura. (Dhawan & Tak, 2004; Hasper et al., 2006). 
Only the previous history of Henoch-Schoenlein purpura and its vasculitis-related coronary 
lesions, could explain the premature infarction of this case. However, Henoch-Schonlein 
purpura and its nephritis regressed and stabilized the last ten years, which is also another 
interesting finding of the present case. 
Co-existence of other predisposing factors for ischemic heart disease, such as thrombophilic 
disorders or potential superimposition of other systemic vasculitis, could also be a possible 
explanation of the unusual severe premature infarction, in the present case. (Eleftheriadis, 
2007b; Shin & Lee, 2007). 
Antiphospholipid syndrome should be excluded in cases of Henoch-Schonlein Purpura, and 
antiphospholipid antibodies should be measured to determine whether prophylactic 
antithrombotic measures are needed to prevent additional thrombotic manifestations. 
(Espinosa & Gervera, 2010; Monastiri et al. 2002; Sullivan et al., 1999). 
However, repeated and meticulous examinations for thrombophilic diathesis, including 
antiphospholipid antibodies, as well as immunological examinations for other secondary 
systemic vasculitis, did not reveal any additional diagnosis in this case. (Eleftheriadis, 
2007b). Moreover, the possibility of polyangitis overlap syndrome was also excluded.  
Although vasculitis is classified according to the size of involved vessels, some patients do 
not belong to a single disease entity and show the symptoms seen in more than two 
diseases. (Tanimoto, 1994; Zaidi et al, 2008).  
The incidence of polyangitis overlap syndrome in patients with cardiac vasculitis is 
unknown, because this overlap has often been diagnosed by postmortem autopsy. (Freddo 
et al., 1999; Kimura et al, 2011; Kumar et al., 2002; Wegner & Schneider, 1996). Therefore, 
when a patient presents with atypical presentation of Henoch-Schonlein Purpura, the 
overlap of other vasculitis should also be examined to prevent unexpected fatal situations. 
(Watanabe et al., 2003; Zaidi et al., 2008). 
Latent vasculitis in the setting of Henoch-Scoenlein purpura was the only obvious cause for 
the severe infarction in this case. No other alarm symptoms for years and no previous signs 
of active vasculitis were reported, which could had lead to preventive measures for 
coronary thrombosis. 
In conclusion, this case is of interest due to rarity of Henoch-Schonlein Purpura as a cause of 
severe coronary artery disease and the atypical presentation with latent course of Purpura-
related vasculitis. 
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3. Coronary artery disease and primary systemic vasculitis 
Primary systemic vasculitides are a group of autoimmune conditions characterized by 
occlusion, stenosis or aneurysmal dilatation of blood vessels, including coronary arteries, 
secondary to intramural inflammation. Increased prevalence of premature cardiovascular 
disease has been observed in chronic inflammatory disorders, such as systemic vasculitis. 
Coronary abnormalities may also be the only manifestations of many vasculitides. (Bijl, 
2003; Kaplan, 2009; Knockaert, 2007; Mukhtyar et al., 2009; Nabatian et al., 2006; Reinhold-
Keller et al, 2005).  
Skin biopsy, showing mural fibrin deposition in arterioles or venules and angiocentric 
inflammatory cell infiltration, in cases with suspicion of vasculitis, is important for early 
diagnosis. (Magro & Crowson, 1999). (Figure 1) 
 
Fig. 1. Skin biopsy from a patient with leukocytoclastic vasculitis showing mural fibrin 
deposition in a venule and angiocentric mixed meutrophilic and lymphocytic infiltration. 
(Magro & Crowson, 1999). 
Although the mechanisms of accelerated atherosclerosis in systemic vasculitis have not been 
fully clarified and may differ in the different vasculitic syndromes, direct injury to arteries, 
arterial intimal –media calcification, pro-atherogenic changes in lipid and fibrin metabolism, 
and systemic hypertension due to alterations in carotid baroreceptor sensitivity, as a 
consequence to vasculitis, have been proposed.( Agarwal et al., 2010; Donald et al., 1976; 
Kane & Keogh, 2009; Mukhtyar, et al., 2009). 
Endothelial cell activation through autoantibodies, resulting in endothelial cell dysfunction, 
complement-dependent and antibody-dependent cytotoxicity, cytokines and direct effect of 
adhesion molecules have all been also implicated in vasculitis-related premature 
atherosclerosis. (Bijl, 2003; Savage, 2002).  
Current therapy has changed the natural history of these diseases from death or severe 
morbidity to a remitting-relapsing condition in most instances. However, despite major 
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immunosuppressive care, systemic vasculitis may lead to potential fatal complications and 
death, through diffuse vessel fibrinoid necrosis and interstitial hemorrhages, attaching 
multiple organs. (Andersson, 2000; Bossert, et al. 2011; Eberhardt & Dhadly, 2007; Freddo et 
al., 1999; Lin, et al., 2007; Osman & McCreery, 2000; Wegner & Schneider, 1996).  
What is more, longer survival, relapsing course and complications related to chronic 
corticosteroid therapy (hypertension, diabetes mellitus and change in lipid profile), may 
further contribute to an increase in cardiovascular events and morbidity. (Lin et al., 2007; 
Mukhtyar et al., 2009).  
On the other hand, there is evidence that glycocorticoid therapy in combination with 
immunosuppressive may improve endothelial dysfunction and prevent myocardial 
ischemia as a consequence of vasculitis in some cases. (Cocco & Gasparyan, 2010; Gonzalez-
Juanatey et al., 2006; Lutz et al., 2009; Oates-Whitehead, et al. 2003). 
Primary systemic vasculitides are categorized according to the vessel size, into large-vessel 
and medium- to small-vessel vasculitis, while the mode and incidence of cardiac 
involvement vary within the different vasculitic syndromes. (Agarwal et al., 2010; Hata & 
Onouchi, 2009; Hewins & Jane, 2010; Kane & Keogh, 2009; Mukhtyar et al., 2009). The 
relation of coronary artery disease with different categories of primary vasculitides are 
reviewed.  
3.1 Cardiovascular involvement in large vessel vasculitis 
3.1.1 Coronary artery disease and giant cel arteritis  
Giant cell arteritis is a relatively common large vessel vasculitis, which affects, 
predominantly cranial nerves, especially temporal artery, occasionally aorta and rarely 
coronary arteries or other visceral or peripheral arteries. (Andersson, 2000). Stroke, aortic 
aneurysm or dissection, and even aortic rupture, visual loss due to ischemic optic 
neuropathy, secondary to temporal arteritis, are tragic manifestations of giant cell arteritis. 
(Andersson, 2000; Eberhardt & Dhadly, 2007; Lin et al., 2007).  
Coronary artery disease is most commonly occurred in the long-term course, but it is also 
reported at disease presentation, in atypical cases. (Bossert et al., 2011; Eberhardt & Dhadly, 
2007; Kimura et al., 2011; Lin, et al., 2007). Giant cell-related early myocardial infarction, 
often with fatal outcome, is more commonly reported than previously appreciated. (Freddo 
et al., 1999; Lin et al., 2007; Bossert et al., 2011; Wegner & Schneider, 1996).  
Although, most of the complications of giant cell arteritis can be effectively prevented by 
early initiation of corticosteroid treatment, severe myocardial infarction, even fatal, can still 
occur despite high-dose corticosteroid therapy. (Andersson, 2000; Bossert et al., 2011; 
Eberhardt & Dhadly, 2007; Freddo et al., 1999; Lin et al., 2007; Wegner & Schneider, 1996). 
Furthermore, in unusual cases of coronary giant arteritis, precise diagnosis was done 
antemortem at autopsy. (Freddo, T., et al., 1999; Kimura, T., et al. 2011; Kumar, P., et al., 
2002; Wegner, M., & Schneider, J. 1996). 
Modern imaging techniques, including positron emission tomography and magnetic 
resonance imaging should be considered in atypical cases of giant cell aortitis and coronary 
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giant arteritis, which are more common than previously thought. (Bossert et al., 2011; 
Kimura et al., 2011; Lin et al., 2007; Mavrogeni et al., 2009). Directional coronary 
atherectomy can also be an alternative diagnostic method for coronary giant arteritis. ;Saito 
et al., 1994). 
3.1.2 Coronary artery disease and Takayasu arteritis 
Takayasu arteritis is a large vessel vasculitis that usually involves the large cardiac vessels, 
predominantly the aorta and its main branches. Approximately 10% of cases are associated 
with ostial or proximal coronary artery stenosis, necessitating bypass. (Amano & Suzuki, 
1992; Ouali et al., 2011; Park et al., 2010, Sheikhzadeh et al., 2002).  
Angiographically Takayasu arteritis was classified as cervicobranchial (I), thoracoabdominal 
(II), peripheral type (III) and generalized type (IV), which was the most frequent. 
(Sheikhzadeh, A. et al. 2002). Atypical presentation of Takayasu arteritis, with acute 
myocardial infarction in young patients, which could not be fully classified, was also 
reported. (Araszkiewicz et al., 2007). 
Coronary artery disease as a consequence of Takayasu arteritis, is relatively rare, resulting 
however in severe life-threatening complications. It is also associated with aneurysmal 
dilation of other arteries such as carotid, vertebral and renal arteries. (Amano & Suzuki, 
1992; Araszkiewicz et al., 2007; Ouali et al., 2011; Sheikhzadeh et al., 2002). 
3.2 Cardiovascular involvement in medium and small vessel vasculitis 
Coronary vasculitis is an uncommon but catastrophic clinical presentation of small and 
medium vessel vasculitis. Inflammation and damage of the coronary arteries lead to 
aneurysm formation and subsequently to stenosis and coronary thrombosis. (Agarwal et al., 
2010; Hata & Onouchi, 2009; Hewins &Jayne, 2010; Kane & Keogh, 2009).  
Prompt diagnosis and early treatment with corticosteroid and immunosuppressives in 
combination to anti-anginic therapy is usually effective and reduced the frequency of 
cardiovascular complications. However, vasculitis relapse although rare, may result in an 
increased risk of cardiovascular disease later in life despite aggressive therapy. (Hewins & 
Jayne, 2010; Kane & Keogh, 2009).  
3.2.1 Coronary artery disease and Kawasaki disease 
Kawasaki disease is an acute systemic vasculitis of childhood, of unknown origin, that 
particularly affects the coronary arteries. It is complicated by coronary arterial aneurysms 
(Figure 2) and stenosis in approximately 20 to 25% of untreated patients and subsequently 
can lead to myocardial infarction and/or sudden death. (De Castro et al., 2009; La Pellegrin 
et al., 2011; Tsuda et al., 2011; Wood & Tulloh, 2009).  
Kawasaki disease has an incidence of approximately 8 per 100000 children in the western 
countries, while it is more frequent in Japan. (Fukazawa & Ogawa, 2009; Hata & Onouchi, 
2009). It is considered one of the most common causes of acquired heart disease in children 
in developed countries. (Caballero-Mora et al., 2011; De Castro et al 2009; Fukazawa & 
Ogawa, 2009; La Pellegrin et al., 2011; Tsuda et al., 2011; Wood & Tulloh, 2009).  
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Fig. 2. Coronary-artery aneurysm in a patient with Kawasaki disease (Hewins & Jayne, 2010). 
Despite treatment of acute phase with intravenous immunoglobulin and aspirin, up to 5% of 
Kawasaki disease patients, still continued to develop serious cardiac life-threatening 
complications, mainly giant coronary aneurysms and thrombotic stenoses, resulted in 
myocardial infarction and/or death. (Caballero-Mora et al., 2011; De Castro et al., 2009; Hata 
& Onouchi, 2009; LaPellegrin et al., 2011; Lin et al., 2011; Tsuda et al., 2011; Wood & Tulloh, 
2009). 
Atypical presentation or incomplete form is presented in one third of all Kawasaki disease 
patients, characterized by an older age at onset and diagnostic delay. (La Pellegrin et al., 
2011; Gomard-Mennesson et al., 2010). 
Acute coronary syndrome in adults caused by Kawasaki disease is rarely reported. 
(LaPellegrin et al., 2011, Tsuda E et al., 2011). Older age, male sex, higher C-reactive protein 
levels, urticarial exanthema, lack of response to the first intravenous immunoglobulin (IVIg) 
infusion and IVIg dosage < 2 g/kg, were reported as risk factors for the development of 
atherosclerosis in adults with Kawasaki disease. (La Pellegrin et al., 2011, Caballero-Mora et 
al 2011). C-reactive protein, oxidative stress, and inflammatory cytokines, are also increased 
in the remote phase of Kawasaki disease (Fukazawa & Ogawa, 2009).  
Despite intensive research the cause remains unknown. It is generally accepted that an as 
yet undefined infectious trigger in a genetically predisposed individual results in Kawasaki 
disease. (Eleftheriou et al., 2009).  
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A strong genetic influence on Kawasaki disease susceptibility has been indicated from 
epidemiological studies. (Hata & Onouchi, 2009). Advances in molecular genetic analysis, 
have permitted the identification of inositol 1,4,5-triphosphate 3-kinase C (ITPKC), as a 
predisposing gene associated with Kawasaki disease. (Eleftheriou et al., 2009; Hata & 
Onouchi, 2009; Lin et al., 2011; Rowley, 2011). 
Early detection and initiation of therapy is substantial for good outcome in Kawasaki 
patients with coronary lesions. The combination of aspirin, corticosteroids and/or 
intravenous immunoglobulin, started early after the onset of symptoms, has reduced the 
frequency of coronary artery aneurysms in Kawasaki disease. (Oates-Whitehead et al., 2003; 
Wooditch & Aronoff, 2005).  
Although there are no clear specific recommendations regarding thrombolytic therapy in 
Kawasaki pediatric patients, there are reports of the use of all known thrombolytics, in 
children with myocardial infarction related to Kawasaki disease. (Paredes et al., 2000). Close 
collaboration between pediatric cardiologists and coronary interventional cardiologists is 
necessary. (Akagi, 2011).  
3.2.2 Coronary artery disease and Henoch Schoenlein Purpura 
Henoch Schoenlein Purpura is one of the most common forms of leukocytoclastic vasculitis 
in children, which is self-limited in the majority of cases. (Lutz et al., 2009; Pillebout et al., 
2002; Polizzotto et al., 2006; Zaidi et al., 2008).  
Infectious triggers are still implicated in the aetiopathogenesis of Henoch-Schoenlein 
purpura, while several genetic polymorphisms have been described that may be relevant in 
disease predisposition or development of disease complications. (Eleftheriou et al., 2009; 
Lutz et al., 2009). In adults clinical presentation of Henoch Schoenelin purpura is severe, 
with relatively poor outcome, worse than in children, which is mainly related to renal 
impairment and glomerulonephritis. (Eleftheriou et al., 2009; Lutz et al., 2009). 
Coronary artery disease in adults with Henoch Schoenelin purpura is rarely reported as 
main manifestation and only in case reports. (Table 1). It should be distinguished from 
secondary Henosch Schoenelin purpura caused for example by rheumatic fever. (Lutz et al., 
2009; Pillebout et al., 2002).  
Patient Sex/Age (y) Cardiac Involvement Treatment Outcome 
Male/71 
(Polizzotto, M.N., 
et al., 2006) 
Complete 
atrioventricular block, 
no myocardial necrosis 
Methylprednisolone, 
pulse therapy 
Complete 
resolution 
Male/69 
(Carmichael, P. et 
al., 2002) 
Creatinine kinase 
increase, left bundle 
branch block 
Methylprednisolone 
Death within  
11 d 
Male/63 
(Agraharkar, M., 
et al 2000) 
Escape rhythm and 
myocardial infarction 
Methylprednisolone 
Death within  
10 d 
Male/14 
(Osman, A., 2000) 
Junctional rhythm, 
troponin T increase 
Prednisone, azathioprine, 
ventricular pacemaker 
Death within a 
few days 
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Patient Sex/Age (y) Cardiac Involvement Treatment Outcome 
Male/24 
(Kereiakes DJ,  
et al., 1984) 
Congestive heart 
failure (biopsy-proven 
immunoglobulin A 
deposits in 
myocardium) 
Prednisone, 
cyclophosphamide 
Persistent 
congestive heart 
failure with low 
ejection fraction 
(18%) 
Male/29 
(Abdel-Hadi, O., 
et al., 1981) 
Myocardial infarction 
without 
macroangiopathy 
— 
Persistent apical 
dyskinesia 
Male/11 
(Lecutier, M.A., 
1952) 
Myocardial necrosis, 
likely secondary HSP 
Penicillin 
Death 1 mo after 
first admission 
Male/64 
(Satoh, M., et al., 
1991) 
Cardiac dysfunction 
and dilatation 
— Unknown 
Male/9 
(Guven, H., et al., 
2006) 
Mobitz type 2 
atrioventricular block, 
likely secondary HSP 
Salicylate, penicillin 
Complete 
resolution 
Male/13 
(Kalyoncu, M.,  
et al., 2006) 
Severe mitral 
insufficiency with 
dilatation of the left 
ventricle, likely 
secondary HSP 
Methylprednisolone, 
cyclophosphamide 
Death 1 mo after 
admission from 
cardiac arrest 
Male/17 
(Zaidi, M., et al., 
2008) 
Left ventricular 
dilatation, likely 
secondary HSP 
Methylprednisolone 
pulse therapy 
Kidney function 
normal at 3-mo 
follow-up, 
cardiac outcome 
unknown 
Male/19 
(Lutz, H., et al., 
2009) 
Myocardial 
involvement, 
arrhythmia 
(atrioventricular 
blocking type 2) 
Methylprednisolone 
pulse therapy, 
Cyclophosphamide pulse 
therapy 
Complete 
resolution 
Male/49 
(Eleftheriadis, D., 
2007) 
Acute myocardial 
infarction 
Salicylate, antianginal 
therapy 
Complete 
resolution 
 
Abbreviation: HSP, Henoch-Schönlein purpura.  
Table 1. Published case reports of coronary artery disease related to Henoch-Schoenlein 
Purpura. (Lutz et al., 2009). 
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Although immunosuppressive therapy, mainly with steroids and/or cyclophosphamide,  
is reported to be insufficient in diminishing the incidence of renal insufficiency, they  
may prevent infarction and deleterious outcome. (Lutz et al., 2009). Different 
immunosuppressive medications and newer therapeutic approaches such as biologic agents 
have been also reported as alternative options for better management. (Eleftheriou et al., 
2009; Lutz et al., 2009; Pillebout et al, 2002;). 
3.2.3 Coronary artery disease and antineutrophilic cytoplasmic antibodies (anca) 
associated vasculitis  
Wegener’s granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome are 
small-to medium vessel vasculitides, with strong association with the presence of anti-
neutrophil cytoplasm antibodies (ANCAs). There are several reports of extensive 
myocardial infarction in young patients, as a consequence of coronary aneurysms, related to 
an ANCA-positive vasculitis. (Mukhtyar et al., 2009; Musuruana et al., 2011). According to 
similar reported cases early treatment with high doses of immunosuppressives such as 
corticosteroids and cyclophosphamide, resulted in aneurysm resolution and may prevent 
myocardial infarction. (Musuruana et al., 2011). 
Churg-Strauss syndrome is a vasculitis associated with asthma and eosinophilia. There are 
two subsets of patients with different pathogenetic mechanisms, with ANCA mediated 
process in ANCA positive patients and tissue infiltration by eosinophils in ANCA negative 
patients. Heart diseases related to Churg-Strauss syndrome include coronary vasculitis, 
myocarditis, valvular heart abnormalities, congestive heart failure and pericarditis. 
Coronary artery disease is significantly more common in ANCA-negative cases and is the 
leading cause of mortality in Churg-Strauss syndrome. (Churg & Strauss, 1951; Keogh & 
Specks, 2003; Sable-Fourtassou et al., 2005; Sinico & Bottero, 2009). 
3.2.3.1 Coronary artery disease and Wegener granulomatous disease 
Wegener’s granulomatosis is one of the most common small-and medium sized necrotizing 
vasculitis that mainly affects the respiratory tract and kidneys. Cardiac manifestations, 
although they are increasingly recognized, are relatively rare and in most cases silent. 
Coronary arteries, pericardium, myocardium, endocardium, valves, conduction system and 
great vessels may be involved. (Korantzopoulos et al., 2004; Suppiah et al., 2011).  
According to substantially increased number of reports Wegener’s vasculitis can manifest as 
myocardial ischemia and infarction. Cardiovascular complications without previous history 
will be also reported in 14% of patients within five years of newly diagnosed Wegener’s 
granulomatosis. (Suppiah et al., 2011). The presence of proteinase 3 (PR3) antineutrophil 
cytoplasmic antibodies (ANCA) is associated with reduced cardiovascular risk in patients 
with vasculitis. (Phillip & Luqmani, 2008; Suppiah et al., 2011).  
Coronary angiography failed to reveal atheroscletotic disease or thrombotic occlusion in 
some reported cases. In similar cases magnetic resonance imaging with adenosine test may 
become the alternative examination to reveal myocardial ischemia, especially 
subendocardial ischemia. (Cocco & Gasparyan, 2010).  
Immunosuppressive therapy with steroids and cyclophosphamide resulted in 
disappearance of myocardial ischemia in reported cases. (Cocco & Gasparyan, 2010; Phillip 
& Luqmani, 2008; Suppiah et al., 2011).  
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3.2.4 Coronary artery disease and polyarteritis nodosa 
Polyarteritis nodosa is an ANCA-negative medium and small vessel vasculitis that 
commonly affects kidneys, gastrointestinal tract, skin, nerves, joints and muscles. There are 
no specific serological markers and diagnosis depends on clinical presentation, angiography 
and tissues biopsy. It can pursue a relapsing course, although treatment with corticosteroids 
and immunosuppressive is usually effective. It is now rarely associated with hepatitis B 
infection. (Hewins & Jayne, 2010). 
Premature coronary artery disease, presenting multiple progressive coronary lesions and 
necessitating repeated percutaneous interventions and/or bypass, has been described in 
several case reports in the context of polyarteritis nodosa. (Maillard-Lefebvre ey al., 2008; 
Yanagawa et al., 2010; Yuce et al., 2011).  
4. Coronary artery disease and secondary systemic vasculitis 
Coronary artery disease as a consequence of secondary systemic vasculitis on the ground of 
autoimmune diseases such as systemic lupus erythematosis, rheumatoid arthritis, primary 
antiphospholipid syndrome etc is the leading cause of morbidity and mortality in these 
cases. It may occur in younger age, it is often asymptomatic and it may be clinically silent in 
early phases. (Caracciolo et al., 2004; Salmon & Roman, 2008; Sitia et al., 2009; Yildiz, 2010; 
Yiu et al., 2011). Arterial compliance and arterial distensibility may be altered via systemic 
inflammation and may lead to accelerated atherosclerosis in secondary systemic vasculitis. 
(Yildiz, 2010).  
Although coronary angiography remains the cold standard for diagnosing coronary 
stenosis, non invasive and more reliable methods, such as magnetic resonance imaging and 
PET scan, have been proposed in order to detect subclinical microcirculation abnormalities. 
(Pennell, & Keenan, 2011; Sitia et al., 2009). 
4.1 Coronary artery disease and systemic lupus erythematosis 
Systemic lupus erythematosis is a chronic autoimmune disease involving multiple organ 
systems, characterizing by flares and remissions and presence of antinuclear autoantibodies. 
Early symptoms most frequently involve the skin and joints. (Kalunian & Merill, 2009).  
Severe lupus morbidity and mortality however, is usually associated with cardiovascular 
events and major organ damage, particularly kidneys. Coronary artery disease was found to 
be the main cause of death in systemic lupus erythematosis in all studies. (Caracciolo et al., 
2004; Gilboe, 2008; Kalunian & Merill, 2009).  
Improved understanding of systemic lupus erythematosis pathogenesis and immunology 
has lead to target treatments, such as this provided by biologic agents, which resulted in 
disease stabilization or even reverse of the disease course. (Kalunian & Merill, 2009;). 
4.2 Coronary artery disease and rheumatoid arthritis 
Secondary vasculitis in the setting of rheumatoid arthritis can affect small as well as large 
vessels, contributing to renal, neurological, gastrointestinal and cardiac complications. High 
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rheumatoid factor levels and cryoglobulins were associated with multi-organ complications 
of rheumatoid vasculitis. (Albada-Kuipers et al., 1986; Solomon, et al., 2003).  
Chronic systemic inflammation contributed to accelerated atherosclerosis in rheumatoid 
arthritis. (Ku et al., 2009; Solomon et al., 2003). Coronary rheumatoid vasculitis although 
rare, is increasingly recognized, can be subclinical, has high mortality rate and in some cases 
can be found only post-mortem. (Abu-Fadel et al., 2011; Albada-Kuipers et al., 1986; Jeffery, 
2010; Solomon et al., 2003). Rapid progression from an ectatic to an aneurysmatic coronary 
artery leading to acute coronary syndrome in rheumatoid vasculitis has been also reported 
and only in case reports. (Abu-Fadel et al., 2011; Wang, K.Y., et al., 1999). 
Other cardiac manifestations of rheumatoid arthritis reported, were valvular disease, 
pericarditis and rarely myocarditis and aortitis. (Solomon, 2003; Abu-Fadel et al., 2011).  
Early diagnosis and prompt initiation of immunosuppressive therapy in coronary 
rheumatoid vasculitis, is crucial in prevention of further coronary aneurysmal expansion 
and rupture. (Abu-Fadel et al., 2011; Wang, K.Y., et al., 1999). According to recent reports, a 
comprehensive cardiac magnetic resonance imaging is considered an effective and less-
invasive method for assessing the microvascular and/or subendocardial ischemic lesions of 
asymptomatic patients with rheumatoid vasculitis. (Kobayashi, Y., et al., 2010; Mavrogeni et 
al., 2009). 
4.3 Coronary artery disease and antiphospholipid syndrome  
Antiphospholipid syndrome is an autoimmune disorder characterized by 
hypercoagulability, arterial and venous thrombosis, recurrent fetal loss and the presence of 
antiphospholipid antibodies. (Kaynar et al., 2007; Benzarouel et al., 2007; Levine et al., 2000; 
Silbiger, 2009).  
It may be primary, without other signs of autoantibodies, besides antiphospholipid 
antibodies or secondary in the setting of underlying disease e.g. malignancy or autoimmune 
diseases, mainly systemic lupus erythematosis. (Kaynar et al., 2007; Sullivan et al., 1999). 
Antiphospholipid antibodies also include the lupus anticoagulant and anticardiolipin 
antibody. (Sullivan et al., 1999; Espinosa & Gervera, 2010).  
Coronary artery disease, especially myocardial infarction in young patients, even silent, has 
been reported in antiphospholipid syndrome, with or without systemic lupus 
erythematosis. (Kaynar et al., 2007; Benzarouel et al., 2007). In similar cases simultaneous 
multiple organ thrombotic signs, including renal vein thrombosis, portal vein thrombosis, 
pulmonary emboli and myocardial infarction, must be excluded by tomographic 
angiography. (Kaynar et al., 2007; Levine et al., 2000; Silbiger, 2009; Tenedios et al., 2006). 
Transesophageal echocardiography is also important for detection of leaflet thickening, 
vegetations and intramural thrombosis in patients with antiphospholipid syndrome and 
vasculitis. (Silbiger, 2009). 
In all cases of coronary artery disease and vasculitis, especially in young patients with no 
other risk factors for heart disease, hypercoagulability should be excluded, mainly 
antiphospholipid syndrome. (Eleftheriadis, D., 2007a; Shin & Lee, 2007; Sullivan et al., 1999). 
Intensive anticoagulation therapy in combination with immunosuppressives is the therapy 
of choice in antiphospholipid syndrome and vasculitis-related thrombosis. This strategy 
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results in disease stabilization and prevention of recurrent thrombotic events. (Kaynar et al., 
2007; Sullivan et al., 1999).  
5. Conclusions 
Primary or secondary systemic vasculitides, although rare and diverse chronic 
inflammatory diseases, resulted in severe and often life-threatening complications, with 
coronary artery disease being the leading cause of morbidity and mortality in these cases. 
Chronic inflammation related to vasculitis resulted in coronary aneurysms, coronary 
stenosis, intramural thrombosis and microcirculation abnormalities, with subsequent 
cardiovascular events, which may occur at younger age and they are often silent in early 
phases.  
In some reported cases the exact diagnosis can be only made postmortem. Severe acute 
myocardial infarction and/or sudden death could also be the first manifestation of coronary 
artery disease related to undiagnosed vasculitis.  
Although coronary angiography remains the gold standard for diagnosing coronary lesions, 
modern non-invasive and more reliable sophisticated imaging techniques, including MRI 
with adenosine test and PET scan, have been introduced into clinical practice. In order to 
detect subclinical intramural thrombosis, coronary micro-aneurysms and microcirculation 
abnormalities, these imaging techniques should be recommended in evaluation of vasculitis-
related cardiovascular disease.  
Early diagnosis of vasculitis and immediate initiation of therapy with corticosteroids and 
immunosuppressives, in addition to intensive anticoagulation, is the only optional strategy 
for good outcome, prevention of further vasculitis progression, regression of early lesions 
and prevention of further thrombotic events. However, despite intensive therapy in some 
reports the coronary lesions could not be regressed.  
The close collaboration between cardiologist, rheumatologist, pediatrician and radiologist is 
essential for optional outcome in atypical cases of coronary artery disease related to 
vasculitis. 
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